Manuel Hildago

10PUBLICATIONS
80CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 26, 2026
Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial.

|Nov 04, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.

Pascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade

|Nov 14, 2024
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.

Francesca Sarno, Jair Tenorio, Sofia Perea

|Sep 21, 2023
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.

Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D Jafari

|Mar 27, 2023
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.

Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim

|Jul 01, 2022
Facts and Hopes in Immunotherapy of Pancreatic Cancer.

Bruno Bockorny, Joseph E Grossman, Manuel Hidalgo

Pageof 2

Frequent Collaborators

3 joint publications

Rocio Garcia-Carbonero

3 joint publications

Bruno Bockorny

3 joint publications

Manish A Shah

2 joint publications

Laura Medina Rodriguez